Who are Somagenetix's investors?

Somagenetix's investors include VI Partners, Verve Ventures.

Somagenetix

11 employees on LinkedIn · 2 known investors

Somagenetix develops gene therapies for phagocyte disorders using a platform based on lentivirus-transduced stem cells designed for one-time treatments with cellular specificity. Its lead candidate, SGX-001, targets Chronic Granulomatous Disease and is on track for human clinical trials in 2026.

Biotech Deep Tech Healthtech

Investors · 2

VI PartnersAltendorf · $2.2M – $4.5M

Verve Venturesreported · 2 sourcesZug · $1.1M – $2.2M

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AOct 2024
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Somagenetix Raises CHF10M In Series A Financingfinsmes.com · Oct 2024

Somagenetix AG raises CHF 10M to advance its first gene therapy candidate into a clinical trial - Wyss Zurichwysszurich.ch · Oct 2024

Somagenetix AG secures CHF 10 million in Series A financing to advance lentiviral gene therapy for Chronic Granulomatous Disease (CGD)globenewswire.com · Oct 2024

Frequently asked questions

What does Somagenetix do?: Somagenetix develops gene therapies for phagocyte disorders using a platform based on lentivirus-transduced stem cells designed for one-time treatments with cellular specificity. Its lead candidate, SGX-001, targets Chronic Granulomatous Disease and is on track for human clinical trials in 2026.
Who are Somagenetix's investors?: Somagenetix's investors include VI Partners, Verve Ventures.